| 前收市價 | 7.80 |
| 開市 | 7.87 |
| 買盤 | 8.06 x 700 |
| 賣出價 | 8.12 x 600 |
| 今日波幅 | 7.67 - 8.31 |
| 52 週波幅 | 6.86 - 27.35 |
| 成交量 | |
| 平均成交量 | 1,347,198 |
| 市值 | 281.878M |
| Beta 值 (5 年，每月) | 0.47 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -3.05 |
| 業績公佈日 | 2024年5月09日 - 2024年5月13日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 23.13 |
InvestorPlace3 Biotech Stocks to Dump Before They Go to Zero
It is not a bad idea to hunt for biotech stocks to sell. Such stocks have earned a bad reputation among investors, and for good reason. Most biotech companies fail, as their success often hinges on receiving regulatory approval for their products. It is an extremely high-risk sector to invest in. For every promising biotech company that successfully navigates clinical trials and generates multibagger returns, there are 99 others that either fail outright or struggle to deliver any gains at all.
Insider MonkeyWhat Makes RAPT Therapeutics (RAPT) an Investment Choice?
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” fourth-quarter investor letter. A copy of the same can be downloaded here. In the quarter the fund returned 9.15% (net), compared to a 12.75% return for the Russell 2000 Growth Index. For the year, the fund returned 15.96% (net) compared to […]
ZacksShould You Buy RAPT Therapeutics (RAPT) Ahead of Earnings?
RAPT Therapeutics (RAPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
